4.7 Article

Mixed Micelles for Targeted and Efficient Doxorubicin Delivery to Multidrug-Resistant Breast Cancer Cells

期刊

MACROMOLECULAR BIOSCIENCE
卷 16, 期 5, 页码 748-758

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/mabi.201500381

关键词

doxorubicin; hyaluronic acid; mixed micelle; multidrug-resistant cell; pluronic L61; poly(propylene glycol)

资金

  1. Global Innovative Research Center (GiRC) program [NRF-2012K1A1A2A01056094]
  2. National Research Foundation (NRF) - Ministry of Education, Science and Technology, Republic of Korea [NRF-2014R1A2A1A11049772]
  3. National Research Foundation of Korea [2014R1A2A1A11049772, 2012K1A1A2A01056094] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)

向作者/读者索取更多资源

For efficient treatment of multidrug-resistance (MDR) breast cancer cells, design of biocompatible mixed micelles with diverse functional moieties and superior stability is needed for targeted delivery of chemical drugs. In this study, polypropylene glycol (PPG)-grafted hyaluronic acid (HA) copolymers (PPG-g-HA) are used to make mixed micelles with different amounts of pluronic L61, named PPG-g-HA/L61 micelles. Optimized PPG-g-HA/L61 micelles with 3% pluronic L61 exhibit great stability in aqueous solution, superior biocompatibility, and significantly increased uptake into MCF-7 MDR cells via HA-CD44-specific interactions when compared to free doxorubicin (DOX) and other types of micelles. In addition, DOX in PPG-g-HA/L61 micelles with 3% pluronic L61 have toxicity in MCF-7 MDR cells but significantly lower toxicity in fibroblast L929 cells compared to free DOX. Thus, PPG-g-HA/L61 micelles with 3% pluronic L61 content can be a promising nanocarrier to overcome MDR and release DOX in a hyaluronidase-sensitive manner without any toxicity to normal cells.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据